FRA
AVDL

Front Row Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Front Row Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-365
Closed -$2 – 982
2018
Q2 		$2 Buy
365
+16
+5% +$112 ﹤0.01% 820
2018
Q1 		$3K Buy
349
+275
+372% +$2.42K ﹤0.01% 685
2017
Q4 		$1K Buy
+74
New +$694 ﹤0.01% 745

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Front Row Advisors's AVDL Position: Q3 2018 in Review

Front Row Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q3 2018, closing a stake of 365 shares — an estimated $2 sold.

Front Row Advisors first reported a position in AVDL in Q4 2017 and held it in 3 quarters. The position peaked at $3K in Q1 2018. 65 funds tracked by Wall St. Rank hold AVDL as of Q3 2018.

  • Front Row Advisors reported no remaining Avadel Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Front Row Advisors sold 365 Avadel Pharmaceuticals shares in Q3 2018, an estimated $2.
  • Front Row Advisors first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Front Row Advisors's Avadel Pharmaceuticals position peaked at $3K in Q1 2018.
  • 65 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2018.

Based on Front Row Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.